MCL coexpression mm9:1385: Difference between revisions
From FANTOM5_SSTAR
No edit summary |
No edit summary |
||
Line 6: | Line 6: | ||
|ontology_enrichment_disease= | |ontology_enrichment_disease= | ||
|ontology_enrichment_uberon=UBERON:0000073!1.30e-17!54;UBERON:0001049!5.49e-16!52;UBERON:0005068!5.49e-16!52;UBERON:0006241!5.49e-16!52;UBERON:0007135!5.49e-16!52;UBERON:0001017!1.64e-14!73;UBERON:0002346!2.24e-14!64;UBERON:0003075!2.24e-14!64;UBERON:0007284!2.24e-14!64;UBERON:0002020!8.10e-14!34;UBERON:0001016!1.02e-13!75;UBERON:0000955!2.88e-13!47;UBERON:0006238!2.88e-13!47;UBERON:0002616!1.78e-12!46;UBERON:0004121!1.83e-12!95;UBERON:0000924!1.83e-12!95;UBERON:0006601!1.83e-12!95;UBERON:0003080!2.47e-12!40;UBERON:0010371!3.31e-12!73;UBERON:0003056!4.45e-12!49;UBERON:0002780!1.61e-11!39;UBERON:0001890!1.61e-11!39;UBERON:0006240!1.61e-11!39;UBERON:0003528!1.00e-10!29;UBERON:0002791!1.00e-10!29;UBERON:0001893!1.00e-10!29;UBERON:0002420!5.54e-08!8;UBERON:0007245!5.54e-08!8;UBERON:0010009!5.54e-08!8;UBERON:0010011!5.54e-08!8;UBERON:0000454!5.54e-08!8;UBERON:0010314!1.75e-07!92 | |ontology_enrichment_uberon=UBERON:0000073!1.30e-17!54;UBERON:0001049!5.49e-16!52;UBERON:0005068!5.49e-16!52;UBERON:0006241!5.49e-16!52;UBERON:0007135!5.49e-16!52;UBERON:0001017!1.64e-14!73;UBERON:0002346!2.24e-14!64;UBERON:0003075!2.24e-14!64;UBERON:0007284!2.24e-14!64;UBERON:0002020!8.10e-14!34;UBERON:0001016!1.02e-13!75;UBERON:0000955!2.88e-13!47;UBERON:0006238!2.88e-13!47;UBERON:0002616!1.78e-12!46;UBERON:0004121!1.83e-12!95;UBERON:0000924!1.83e-12!95;UBERON:0006601!1.83e-12!95;UBERON:0003080!2.47e-12!40;UBERON:0010371!3.31e-12!73;UBERON:0003056!4.45e-12!49;UBERON:0002780!1.61e-11!39;UBERON:0001890!1.61e-11!39;UBERON:0006240!1.61e-11!39;UBERON:0003528!1.00e-10!29;UBERON:0002791!1.00e-10!29;UBERON:0001893!1.00e-10!29;UBERON:0002420!5.54e-08!8;UBERON:0007245!5.54e-08!8;UBERON:0010009!5.54e-08!8;UBERON:0010011!5.54e-08!8;UBERON:0000454!5.54e-08!8;UBERON:0010314!1.75e-07!92 | ||
|tfbs_overrepresentation_for_novel_motifs=0.491922,0.0600685,0.464605,0.535892,0.346849,0.550971,0.645383,0.691572,0.257202,0.0835344,0.599767,0.632897,0.692139,0.6581,0.364314,0,0.856992,0.338549,0.232269,0.86893,0.426133,0.108444,0.657163,0.345236,0.472505,0.686615,0.63639,0.572827,0.394364,0.181062,0.558142,0.960397,0.336199,0.204204,0.364821,0.335531,0.326478,0.629145,0.303703,0.27383,0.342638,0.56353,0.327433,0.366415,0.161543,0.524258,0.77511,0.589246,0.594982,0.397446,0.839084,0.714419,0.174327,1.10437,1.12205,0.66551,0.406788,0.619643,0.21472,0.663395,0.939962,0.724164,0.269393,0.827522,0.677043,0.869046,1.2599,1.61148,0.935192,1.46355,0.444872,0.253541,0.11437,1.156,0.599223,1.08629,0.589776,0.763395,0.922432,0.430551,1.30789,0.874787,0.722675,0.240896,1.03903,0.0539203,1.75124,0.181203,0.780154,1.77427,1.33021,1.04409,0.973447,0.9304,0.2995,1.40549,0.685716,0.976308,0.775372,0.938145,3.2853,0.960112,1.08669,0.839694,0.838613,0.563071,0.8998,0.585058,0.435642,0.428007,0.484547,1.0885,0.431734,0.605144,1.33732,0.340765,0.0704207,0.53982,0.858327,0.322606,1.16147,0.805995,0.688501,0.762461,1.39185,0.926209,0.65384,0.966541,1.25836,0.356163,1.06946,0.52828,1.2285,0.679647,1.35909,4.5087,0.500709,0.564999,1.30952,2.14327,1.74232,1.26465,0.700956,0.971067,0.831964,0.564002,0.778321,2.10357,1.25623,0.348692,0.540361,0.0987301,1.10596,0.287383,0.678689,1.18867,0.71546,0.376898,0.48935,0.500417,1.31911,1.03816,0.926663,0.482185,0.82857,1.60971,0.325308,0.63125,0.131395 | |||
}} | }} |
Revision as of 19:50, 26 November 2012
Phase1 CAGE Peaks
Short description | |
---|---|
Mm9::chr16:7149860..7149888,+ | p@chr16:7149860..7149888 + |
Mm9::chr16:7150004..7150009,+ | p@chr16:7150004..7150009 + |
Mm9::chr16:72027706..72027715,+ | p@chr16:72027706..72027715 + |
Mm9::chr6:15147087..15147102,+ | p@chr6:15147087..15147102 + |
Mm9::chr6:6813551..6813570,+ | p5@Dlx6 |
Mm9::chr6:6817869..6817879,+ | p@chr6:6817869..6817879 + |
Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data
GO ID | GO name | FDR corrected p-value |
---|---|---|
GO:0031223 | auditory behavior | 0.00624554867692982 |
GO:0042297 | vocal learning | 0.00624554867692982 |
GO:0007638 | mechanosensory behavior | 0.011369759253142 |
GO:0048745 | smooth muscle development | 0.011369759253142 |
GO:0043565 | sequence-specific DNA binding | 0.011369759253142 |
GO:0009790 | embryonic development | 0.011369759253142 |
GO:0010464 | regulation of mesenchymal cell proliferation | 0.0124883598790944 |
GO:0010463 | mesenchymal cell proliferation | 0.0124883598790944 |
GO:0002053 | positive regulation of mesenchymal cell proliferation | 0.0124883598790944 |
GO:0016566 | specific transcriptional repressor activity | 0.0136225454466081 |
GO:0048286 | alveolus development | 0.0136225454466081 |
GO:0050679 | positive regulation of epithelial cell proliferation | 0.0156078834662755 |
GO:0009612 | response to mechanical stimulus | 0.0157798799834461 |
GO:0003700 | transcription factor activity | 0.0157798799834461 |
GO:0022037 | metencephalon development | 0.0176233794549311 |
GO:0021549 | cerebellum development | 0.0176233794549311 |
GO:0050678 | regulation of epithelial cell proliferation | 0.0176233794549311 |
GO:0050673 | epithelial cell proliferation | 0.0214947659182327 |
GO:0030902 | hindbrain development | 0.027580886706257 |
GO:0007612 | learning | 0.0305629476379068 |
GO:0046982 | protein heterodimerization activity | 0.0320469327081517 |
GO:0030326 | embryonic limb morphogenesis | 0.0320469327081517 |
GO:0035113 | embryonic appendage morphogenesis | 0.0320469327081517 |
GO:0030324 | lung development | 0.0320469327081517 |
GO:0030323 | respiratory tube development | 0.0320469327081517 |
GO:0007611 | learning and/or memory | 0.0320469327081517 |
GO:0035107 | appendage morphogenesis | 0.0320469327081517 |
GO:0035108 | limb morphogenesis | 0.0320469327081517 |
GO:0048736 | appendage development | 0.0320469327081517 |
GO:0060173 | limb development | 0.0320469327081517 |
GO:0006355 | regulation of transcription, DNA-dependent | 0.0320469327081517 |
GO:0006351 | transcription, DNA-dependent | 0.0320469327081517 |
GO:0032774 | RNA biosynthetic process | 0.0320469327081517 |
GO:0003677 | DNA binding | 0.0320469327081517 |
GO:0007519 | skeletal muscle development | 0.0320469327081517 |
GO:0045449 | regulation of transcription | 0.0320469327081517 |
GO:0048856 | anatomical structure development | 0.0320469327081517 |
GO:0019219 | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process | 0.0320469327081517 |
GO:0042803 | protein homodimerization activity | 0.0320469327081517 |
GO:0006350 | transcription | 0.0320469327081517 |
GO:0010468 | regulation of gene expression | 0.0334005305199739 |
GO:0031323 | regulation of cellular metabolic process | 0.0352996593287968 |
GO:0014706 | striated muscle development | 0.0352996593287968 |
GO:0007275 | multicellular organismal development | 0.0352996593287968 |
GO:0019222 | regulation of metabolic process | 0.0354612481091163 |
GO:0016070 | RNA metabolic process | 0.0365458237090462 |
GO:0000122 | negative regulation of transcription from RNA polymerase II promoter | 0.0370658451526354 |
GO:0016564 | transcription repressor activity | 0.0396495844999568 |
GO:0007517 | muscle development | 0.0417780806289334 |
GO:0009628 | response to abiotic stimulus | 0.0417780806289334 |
GO:0042802 | identical protein binding | 0.041929498409596 |
GO:0008284 | positive regulation of cell proliferation | 0.042074881854482 |
GO:0007420 | brain development | 0.0427983996470997 |
GO:0045892 | negative regulation of transcription, DNA-dependent | 0.0427983996470997 |
GO:0010467 | gene expression | 0.0427983996470997 |
GO:0046983 | protein dimerization activity | 0.0427983996470997 |
GO:0048598 | embryonic morphogenesis | 0.0427983996470997 |
GO:0035295 | tube development | 0.0427983996470997 |
GO:0003676 | nucleic acid binding | 0.0427983996470997 |
GO:0032502 | developmental process | 0.0448239364889525 |
GO:0007417 | central nervous system development | 0.0468822209526583 |
GO:0006139 | nucleobase, nucleoside, nucleotide and nucleic acid metabolic process | 0.0468822209526583 |
GO:0016481 | negative regulation of transcription | 0.0468822209526583 |
GO:0045934 | negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process | 0.0494229147682189 |
Relative expression of the co-expression cluster over median <br>Analyst:
Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br><br>
Ontology term | p-value | n |
---|---|---|
CNS neuron (sensu Vertebrata) | 3.12e-15 | 23 |
neuroblast (sensu Vertebrata) | 3.12e-15 | 23 |
neuron | 2.45e-08 | 33 |
neuronal stem cell | 2.45e-08 | 33 |
neuroblast | 2.45e-08 | 33 |
electrically signaling cell | 2.45e-08 | 33 |
Ontology term | p-value | n |
---|---|---|
regional part of nervous system | 1.30e-17 | 54 |
neural tube | 5.49e-16 | 52 |
neural rod | 5.49e-16 | 52 |
future spinal cord | 5.49e-16 | 52 |
neural keel | 5.49e-16 | 52 |
central nervous system | 1.64e-14 | 73 |
neurectoderm | 2.24e-14 | 64 |
neural plate | 2.24e-14 | 64 |
presumptive neural plate | 2.24e-14 | 64 |
gray matter | 8.10e-14 | 34 |
nervous system | 1.02e-13 | 75 |
brain | 2.88e-13 | 47 |
future brain | 2.88e-13 | 47 |
regional part of brain | 1.78e-12 | 46 |
ectoderm-derived structure | 1.83e-12 | 95 |
ectoderm | 1.83e-12 | 95 |
presumptive ectoderm | 1.83e-12 | 95 |
anterior neural tube | 2.47e-12 | 40 |
ecto-epithelium | 3.31e-12 | 73 |
pre-chordal neural plate | 4.45e-12 | 49 |
regional part of forebrain | 1.61e-11 | 39 |
forebrain | 1.61e-11 | 39 |
future forebrain | 1.61e-11 | 39 |
brain grey matter | 1.00e-10 | 29 |
regional part of telencephalon | 1.00e-10 | 29 |
telencephalon | 1.00e-10 | 29 |
basal ganglion | 5.54e-08 | 8 |
nuclear complex of neuraxis | 5.54e-08 | 8 |
aggregate regional part of brain | 5.54e-08 | 8 |
collection of basal ganglia | 5.54e-08 | 8 |
cerebral subcortex | 5.54e-08 | 8 |
structure with developmental contribution from neural crest | 1.75e-07 | 92 |
TFBS overrepresentation<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data
Novel motifs
JASPAR motifs
Motifs | -log10(p-value) |
---|---|
{{{tfbs_overrepresentation_jaspar}}} |